Yunkang Group Limited Stock

Equities

2325

KYG9889T1067

Healthcare Facilities & Services

Market Closed - Hong Kong S.E. 04:09:00 2024-05-03 am EDT 5-day change 1st Jan Change
11.1 HKD 0.00% Intraday chart for Yunkang Group Limited -0.18% -9.76%

Financials

Sales 2024 * 979M 135M 1.06B Sales 2025 * 1.09B 150M 1.18B Capitalization 6.18B 854M 6.67B
Net income 2024 * -25M -3.45M -26.97M Net income 2025 * 30M 4.14M 32.36M EV / Sales 2024 * 5.75 x
Net cash position 2024 * 547M 75.55M 590M Net cash position 2025 * - 0 0 EV / Sales 2025 * 5.67 x
P/E ratio 2024 *
-257 x
P/E ratio 2025 *
206 x
Employees 1,510
Yield 2024 *
32.6%
Yield 2025 *
32.9%
Free-Float 25.97%
More Fundamentals * Assessed data
Dynamic Chart
1 week-0.18%
1 month+0.36%
3 months-0.36%
6 months-6.72%
Current year-9.76%
More quotes
1 week
10.98
Extreme 10.98
11.12
1 month
10.96
Extreme 10.96
11.18
Current year
10.04
Extreme 10.04
12.30
1 year
10.04
Extreme 10.04
14.88
3 years
6.60
Extreme 6.6
19.18
5 years
6.60
Extreme 6.6
19.18
10 years
6.60
Extreme 6.6
19.18
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 18-07-19
Director of Finance/CFO 45 21-02-06
Corporate Officer/Principal 58 -
Members of the board TitleAgeSince
Director/Board Member 67 -
Director/Board Member 52 -
Director/Board Member 64 23-08-29
More insiders
Date Price Change Volume
24-05-03 11.1 0.00% 40,000
24-05-02 11.1 0.00% 33,500
24-04-30 11.1 -0.18% 57,500
24-04-29 11.12 0.00% 194,780
24-04-26 11.12 +0.36% 61,500

Delayed Quote Hong Kong S.E., May 03, 2024 at 04:09 am EDT

More quotes
Yunkang Group Ltd is a China-based Company mainly engaged in the provision of diagnosis testing services. The Company operates three segments. Diagnosis Testing segment provides diagnosis testing to hospital and non-medical clients, mainly including routine diagnostic testing, routine pathological examination, infectious disease diagnostic testing, genetic disease diagnostic testing and early cancer detection. Hospital Management Business segment provides management services for the community clinics. Research & Development Institution segment is engaged in the research and development of testing kits. The Company primarily provides services for hospitals and other medical institutions, and commercial entities such as financial institutions and insurance companies.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
10.28 CNY
Average target price
12.93 CNY
Spread / Average Target
+25.72%
Consensus

Annual profits - Rate of surprise